Gene silencing therapeutics market seen reaching $8.49B by 2030

The gene silencing therapeutics market is projected to grow from $4 billion in 2025 to $8.49 billion by 2030, driven by personalized medicine, RNA-based therapies and expanding use in oncology and neurological disorders. North America held the largest share in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Gene silencing therapeutics aim to switch off disease-causing genes before harmful proteins are produced. - The market outlook signals rising demand for more precise treatments for genetic disorders, rare diseases, cancer and neurological conditions. - Growth in personalized medicine could speed adoption of therapies tailored to a patient’s genetic profile and disease biology.

What happened: - The gene silencing therapeutics market is projected to rise from $4 billion in 2025 to $4.64 billion in 2026. - The forecast implies a 16.1% compound annual growth rate during the historical period cited in the report. - The market is expected to reach $8.49 billion by 2030, growing at a 16.3% CAGR. - The Business Research Company published the outlook and made the full report available online: View the full report. - The company also offered a free sample report: Download a free sample.

The details: - Rising genetic disease rates, more investment in molecular medicine research and stronger clinical success for RNA-based therapies are supporting the near-term market expansion. - The long-term forecast also points to more commercialization of gene silencing therapies and a deeper pipeline of precision genetic medicines. - More regulatory approvals for gene therapies are expected to support adoption. - Expanded use in oncology and neurological disorders is another growth driver. - Broader adoption of personalized medicine is expected to lift demand for targeted therapies with fewer adverse effects. - Gene silencing therapeutics use molecular methods to target messenger RNA before defective proteins form. - The market report flags broader use of RNA interference-based treatments and antisense oligonucleotide platforms as key trends. - The report also highlights advances in delivery technologies and more clinical research on next-generation therapies.

Between the lines: - The market forecast reflects a broader shift in drug development toward precision medicine rather than one-size-fits-all treatment. - Personalized medicine matters here because gene silencing can be matched to specific genetic drivers of disease. - The report cites a February 2024 Personalized Medicine Coalition update showing the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region in the coming years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - More gene silencing therapies are likely to move toward commercialization as the pipeline matures. - Regulatory decisions and delivery advances will be key to whether the market reaches the forecasted 2030 size. - Clinical research in rare diseases, oncology and neurology will help determine where adoption grows fastest. - The Business Research Company said its 2026 market reports now include TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - Gene silencing therapeutics are moving from a niche scientific platform toward a larger commercial market, with personalized medicine and RNA-based drug development doing most of the heavy lifting.